Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Gains from Investment Securities: 2021-2025

Historic Gains from Investment Securities for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $3.8 million.

  • Kiniksa Pharmaceuticals International's Gains from Investment Securities rose 37930.00% to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.3 million, marking a year-over-year increase of 58.26%. This contributed to the annual value of $9.7 million for FY2024, which is 16.07% down from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported Gains from Investment Securities of $3.8 million as of Q3 2025, which was up 380,200.00% from $1,000 recorded in Q2 2025.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Gains from Investment Securities ranged from a high of $10.0 million in Q2 2023 and a low of -$3.3 million during Q1 2023.
  • Over the past 3 years, Kiniksa Pharmaceuticals International's median Gains from Investment Securities value was $2.5 million (recorded in 2024), while the average stood at $2.0 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first plummeted by 1,292.64% in 2022, then skyrocketed by 37,930.00% in 2025.
  • Kiniksa Pharmaceuticals International's Gains from Investment Securities (Quarterly) stood at $4.9 million in 2021, then increased by 23.35% to $6.1 million in 2022, then slumped by 121.58% to -$1.3 million in 2023, then spiked by 292.38% to $2.5 million in 2024, then surged by 37,930.00% to $3.8 million in 2025.
  • Its Gains from Investment Securities was $3.8 million in Q3 2025, compared to $1,000 in Q2 2025 and $3.0 million in Q1 2025.